| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -26.5 | -59.1 |
| EPS (diluted, $ a share) | $-0.51 | $-10.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BRVE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Braveheart Bio, Inc.: key numbers
- Share price
- $18.78Close, Nov 17
- Market cap
- $1.69B
- Shares outstanding
- 90.04MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Braveheart Bio, Inc.
All →Braveheart Bio Financial Results
Braveheart Bio reported third quarter 2026 financial results, ending the period with $503.5 million in cash and investments, providing a runway into 2029. The company highlighted 52-week clinical data for BHB-1893 in obstructive HCM and outlined an updated Phase 3 development strategy designed to simplify dosing and minimize titration.
- Term
- Q3 2026
“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work. The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”
Travis Murdoch, M.D., President and Chief Executive Officer
Braveheart Bio Clinical Trial Data
Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The results showed meaningful improvements in exercise capacity (pVO2) and patient-reported outcomes, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg at Week 52.
- Counterparty
- Hengrui Pharma
- Term
- 52 weeks